What about BCS II, (III), IV? [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2015-09-18 14:25 (3929 d 12:30 ago) – Posting: # 15429
Views: 8,981

Hi Shuanghe & all,

of course you are perfectly right. :-D

One should always try to develop a suitable in vitro method.
However, I have some doubts whether matching profiles (ƒ2, Mahalanobis distance, what­so­ever) for BCS classes II, IV (and III except weak acids; qualitatively/quantitatively iden­ti­cal excipients) could ever be of any re­le­vance for the in vivo performance. I wonder whether someone got a response from an agency like this:

Bioequivalence between the formulation applied for and the brand leader product has been demonstrated in vivo and similarity of dissolution profiles could be de­mon­strated in vitro. However, the drug does not belong to BCS Class I; as a con­sequence if any future changes in the formulation are proposed the com­pa­ri­son of dissolution profiles cannot be used as similarity of formulations and new bio­equi­va­lence studies have to be carried out.


Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
156 visitors (0 registered, 156 guests [including 32 identified bots]).
Forum time: 02:55 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5